USA |NASDAQ |USD
| Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
|---|---|---|---|---|
| Mar 28, 2022 | Dec 2021 | $0.00 | - | $0.98 |
| Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
|---|---|---|---|---|
| Mar 28, 2022 | Dec 2021 | $250.00K | - | $0.00 |
Bellicum Pharmaceuticals, Inc's next earnings date is Monday, Mar 28, 2022 for the fiscal quarter ending Dec 2021.
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 0 | $0.00 | $0.00 | $0.00 |
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|
| Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
|---|---|---|---|---|
| Dec 2022 | 0 / 0 | $-2.93 | $-2.93 | $-2.93 |
| Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
|---|
| Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
|---|---|---|---|---|
| Dec 2022 | 1 | $0.00 | $0.00 | $0.00 |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Aug 12, 2021 | Jun 2021 | $-0.85 | $-0.22 | 74.12% |
| May 14, 2021 | Mar 2021 | $-1.37 | $-1.12 | 18.25% |
| Mar 30, 2021 | Dec 2020 | $-1.06 | $0.98 | 192.45% |
| Nov 5, 2020 | Sep 2020 | $-3.15 | $-0.18 | 94.28% |
| Aug 6, 2020 | Jun 2020 | $-2.87 | $-8.55 | -197.91% |
| May 7, 2020 | Mar 2020 | $-2.73 | $1.09 | 139.93% |
| Mar 12, 2020 | Dec 2019 | $-4.34 | $-5.82 | -34.26% |
| Nov 6, 2019 | Sep 2019 | $-5.30 | $-6.80 | -28.30% |
| Aug 5, 2019 | Jun 2019 | $-5.40 | $-5.80 | -7.41% |
| May 7, 2019 | Mar 2019 | $-5.82 | $-5.50 | 5.50% |
| Mar 12, 2019 | Dec 2018 | $-6.46 | $-6.30 | 2.48% |
| Nov 6, 2018 | Sep 2018 | $-5.68 | $-5.50 | 3.08% |
| Aug 7, 2018 | Jun 2018 | $-5.63 | $-6.00 | -6.67% |
| May 8, 2018 | Mar 2018 | $-7.04 | $-6.80 | 3.45% |
| Mar 13, 2018 | Dec 2017 | $-6.97 | $-6.60 | 5.33% |
| Nov 7, 2017 | Sep 2017 | $-7.40 | $-7.10 | 4.05% |
| Aug 8, 2017 | Jun 2017 | $-6.63 | $-7.40 | -11.64% |
| May 8, 2017 | Mar 2017 | $-7.04 | $-8.00 | -13.68% |
| Mar 13, 2017 | Dec 2016 | $-7.33 | $-7.40 | -0.97% |
| Nov 9, 2016 | Sep 2016 | $-6.34 | $-6.60 | -4.10% |
| Aug 8, 2016 | Jun 2016 | $-5.80 | $-6.10 | -5.17% |
| May 9, 2016 | Mar 2016 | $-5.10 | $-5.60 | -9.80% |
| Mar 14, 2016 | Dec 2015 | $-4.20 | $-6.30 | -50.00% |
| Nov 9, 2015 | Sep 2015 | $-0.38 | $-0.51 | -34.21% |
| Aug 13, 2015 | Jun 2015 | $-0.49 | $-0.40 | 18.37% |
| May 11, 2015 | Mar 2015 | $-0.30 | $-0.30 | - |
| Mar 11, 2015 | Dec 2014 | $-0.37 | $-2.02 | -445.95% |
| Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
|---|---|---|---|---|
| Mar 30, 2021 | Dec 2020 | $-8.70 | $-6.66 | - |
| Mar 12, 2020 | Dec 2019 | $-22.17 | $-23.92 | - |
| Mar 12, 2019 | Dec 2018 | $-2.37 | $-24.60 | - |
| Mar 13, 2018 | Dec 2017 | $-2.94 | $-29.10 | - |
| Mar 13, 2017 | Dec 2016 | - | $-25.70 | - |
| Mar 14, 2016 | Dec 2015 | - | $-7.51 | - |
| Mar 11, 2015 | Dec 2014 | - | $-2.02 | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Aug 12, 2021 | Jun 2021 | $250.00K | $700.00K | 2.80% |
| May 14, 2021 | Mar 2021 | $250.00K | $0.00 | - |
| Mar 30, 2021 | Dec 2020 | $250.00K | $0.00 | - |
| Nov 5, 2020 | Sep 2020 | $250.00K | $0.00 | - |
| Aug 6, 2020 | Jun 2020 | $900.00K | $0.00 | - |
| May 7, 2020 | Mar 2020 | $400.00K | $5.13M | 12.83% |
| Mar 12, 2020 | Dec 2019 | $630.00K | $5.13M | 8.15% |
| Nov 6, 2019 | Sep 2019 | $1.20M | $103.00K | 0.09% |
| Aug 5, 2019 | Jun 2019 | $750.00K | $1.39M | 1.85% |
| May 7, 2019 | Mar 2019 | $650.00K | $516.00K | 0.79% |
| Mar 12, 2019 | Dec 2018 | $1.19M | $312.00K | 0.26% |
| Nov 6, 2018 | Sep 2018 | $110.00K | $292.00K | 2.65% |
| Aug 7, 2018 | Jun 2018 | $70.00K | $362.00K | 5.17% |
| May 8, 2018 | Mar 2018 | $30.00K | $154.00K | 5.13% |
| Mar 13, 2018 | Dec 2017 | $980.00K | $-69.00K | - |
| Nov 7, 2017 | Sep 2017 | $30.00K | $126.00K | 4.20% |
| Aug 8, 2017 | Jun 2017 | $80.00K | $128.00K | 1.60% |
| May 8, 2017 | Mar 2017 | - | $128.00K | - |
| Mar 13, 2017 | Dec 2016 | - | $81.00K | - |
| Nov 9, 2016 | Sep 2016 | - | $114.00K | - |
| Aug 8, 2016 | Jun 2016 | - | $101.00K | - |
| May 9, 2016 | Mar 2016 | - | $92.00K | - |
| Mar 14, 2016 | Dec 2015 | - | $34.00K | - |
| Nov 9, 2015 | Sep 2015 | - | $57.00K | - |
| Aug 13, 2015 | Jun 2015 | - | $84.00K | - |
| May 11, 2015 | Mar 2015 | - | $107.00K | - |
| Mar 11, 2015 | Dec 2014 | - | $15.00K | - |
| Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
|---|---|---|---|---|
| Mar 30, 2021 | Dec 2020 | $0.00 | $500.00 | - |
| Mar 12, 2020 | Dec 2019 | $2.48M | $7.14M | 188.02% |
| Mar 12, 2019 | Dec 2018 | $1.97M | $1.12M | -43.15% |
| Mar 13, 2018 | Dec 2017 | $1.12M | $185.00K | -83.48% |
| Mar 13, 2017 | Dec 2016 | - | $388.00K | - |
| Mar 14, 2016 | Dec 2015 | - | $282.00K | - |
| Mar 11, 2015 | Dec 2014 | - | $1.78M | - |
BLCM's next earnings date is Monday, Mar 28, 2022 for the fiscal quarter ending Dec 31, 2021.
According to analysts, the average EPS estimation for Bellicum Pharmaceuticals, Inc's next quarterly earnings is $0.00, with a low EPS estimation of $0.00, and a high estimation of $0.00.
Over the last 1 month, EPS estimates have seen 0 upward revisions and 0 downward. The EPS 1 month trend is $-0.92, the last 2 month trend is $-0.92, and the 3 month trend is $-0.92.
Based on analysts, the average revenue estimation is $250.00K, with a low revenue estimation of $250.00K, and a high estimation of $250.00K.
Bellicum Pharmaceuticals, Inc's previous earnings date was Nov 3, 2021 for its fiscal quarter ended Sep 30, 2021.
Bellicum Pharmaceuticals, Inc's previous annual earnings date was Mar 30, 2021 for its fiscal year ended Dec 31, 2020.
BLCM's earnings per share (EPS) was $-6.66, beating the consensus analysts forecast of $-8.70 by -23.45% , and higher than the previous year's EPS (Dec 2019) by -72.16%.
Revenues were $500.00.
The company reported a net income of $-7.72K.
Bellicum Pharmaceuticals, Inc reported a free cash flow of $-55.38M for its fiscal year, compared to $-78.09M a year ago.
The company ended the fiscal year with $825.00K in total debt, a decrease of -97.78% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.
